Onbrez Breezhaler, INN-indacaterol
نویسنده
چکیده
منابع مشابه
Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea
BACKGROUND Inhaled indacaterol (Onbrez Breezhaler), a long-acting β2-agonist, is approved in over 100 countries, including South Korea, as a once-daily bronchodilator for maintenance and treatment of chronic obstructive pulmonary disease (COPD). Here, we present an interim analysis of a post-marketing surveillance study conducted to evaluate the real-world safety and effectiveness of indacatero...
متن کاملA cross-sectional study to assess inhalation device handling and patient satisfaction in COPD
Delivery of inhaled medications via an inhaler device underpins the effectiveness of treatment for patients with chronic obstructive pulmonary disease (COPD). Correct inhaler technique among patients is also a predictor of achieving treatment compliance and adherence. Reporting of patient satisfaction with inhalers is therefore gaining increasing attention and is now recognized as an important ...
متن کاملLack of clinically relevant differences between combination therapy and monotherapy in COPD.
BATEMAN et al. [1] reported significantly greater mean improvements with indacaterol/glycopyrronium combination therapy, Ultibro Breezhaler (QVA149) compared to monotherapy with either indacaterol (0.07 L), glycopyrronium (0.09 L) or tiotropium (0.08 L) for the primary outcome of trough forced expiratory volume in 1 s (FEV1) at week 26 in patients with chronic obstructive pulmonary disease (COP...
متن کاملRole of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device (Ultibro, Breezhaler), often called QVA149, was first approved in 2013 in Japan and Europe. As of November 2014, more than 40 countries had approved this medication except for the USA. This is the first dual bronchodilator in one device. Now, the Breezhaler is the only device that can provi...
متن کاملNew once-daily, long-acting inhaled β₂-agonist: what role will it play in the treatment of chronic obstructive pulmonary disease?
381 Chronic obstructive pulmonary disease (COPD) is a progressive, life‐threatening respiratory disease that affects 210 million people worldwide includ‐ ing up to 82 million in Europe. Over the last de‐ cade, major clinical trials have allowed us to bet‐ ter refine our approach to clinical management and to solidify best practice with evidence‐based medicine. Bronchodilators remain the corners...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2009